If anyone is interested in preclinical study published in 2023 grom across the globe which fully supports how the drug is specifically made to only target TRPC channels 3,6,7 and the reason why the answer is below. Channels 4 and 5 have been studied to protect the brain during traumatic events. NYR-B03 only targets channels 3,6 and 7 for calcium influx and the first drug of its kind. This is a completely new drug class and a stable drug which can be made in a multitude of drug forms
If anyone is interested in preclinical study published in 2023...
Add NYR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.5¢ |
Change
-0.015(10.7%) |
Mkt cap ! $22.77M | |||
| Open | High | Low | Value | Volume |
| 13.0¢ | 14.0¢ | 12.5¢ | $124.3K | 958.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 116177 | 12.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.0¢ | 10528 | 1 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| NYR (ASX) Chart |